All data are based on the daily closing price as of October 8, 2025
a

ABL Bio

298380.KQ
68.08 USD
0.35
+0.52%

Overview

Last close
68.08 usd
Market cap
3.30B usd
52 week high
77.86 usd
52 week low
15.54 usd
Target price
59.9 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
48.768
Price/Book Value
25.7204
Enterprise Value
3.20B usd
EV/Revenue
48.0588
EV/EBITDA
-32.1061

Key financials

Revenue TTM
66.59M usd
Gross Profit TTM
66.55M usd
EBITDA TTM
-13.60M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
180.43M usd
Net debt
N/A usd

About

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea.
  • Symbol
    298380.KQ
  • Exchange
    KQ
  • Isin
    KR7298380007
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Sang Hoon Lee Ph.D.
  • Headquarter
    Seoul
  • Web site
    https://www.ablbio.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top